Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination

This publication has 10 references indexed in Scilit:

• Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
  Blood, 2022
• Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer
  European Journal of Cancer, 2021
• Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
  European Journal of Cancer, 2021
• Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses
  Journal of Thoracic Oncology, 2021
• Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years
  JAMA, 2021
• Waning Immunity after the BNT162b2 Vaccine in Israel
  New England Journal of Medicine, 2021
• Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer
  Cancer Cell, 2021
• Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
  Nature Medicine, 2021
• Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study
  Acta Oncologica, 2021
• Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study
  The Lancet Oncology, 2020